Restasis vs Tyrvaya
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Restasis | US Tyrvaya | |
|---|---|---|
| Generic name | cyclosporine ophthalmic emulsion | varenicline nasal spray |
| Drug class | Calcineurin Inhibitor (Eye Drop) | Nicotinic Acetylcholine Receptor Agonist (Nasal) |
| Treats | Chronic dry eye | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | AbbVie (Allergan) | Viatris |
| Year approved | 2003 | 2021 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $100M | — |
| Common side effects | Burning sensation, Eye redness, Watery eyes, Blurred vision | Sneezing, Cough, Throat irritation, Nose irritation |
Frequently asked questions
Is Restasis or Tyrvaya better?
Neither is universally "better." Restasis (cyclosporine ophthalmic emulsion) and Tyrvaya (varenicline nasal spray) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Restasis and Tyrvaya?
Restasis is a Calcineurin Inhibitor (Eye Drop) made by AbbVie (Allergan), while Tyrvaya is a Nicotinic Acetylcholine Receptor Agonist (Nasal) made by Viatris. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Restasis has the larger estimated TV advertising budget of the two.